NEUCHÂTEL, Switzerland, May 30, 2012 /PRNewswire/ --
The Reaxys® PhD Prize awards original and innovative research in organic, organometallic and inorganic chemistry
Reaxys today announced the 45 finalists for the 2012 Reaxys PhD Prize. This highly prestigious international prize is open to all students studying for (or having completed in the last 12 months) a PhD in chemistry. The prize recognizes research and publication excellence in organic, inorganic, and organometallic chemistry. All entries were reviewed by a board of more than 80 leading international chemists and judged for originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
"The Reaxys PhD Prize is the premier prize celebrating the very best research being performed by young chemists at the world's leading chemistry departments" said Dr. David Evans, Scientific Affairs Director at Reed Elsevier Properties SA. "We received over 350 submissions. These 45 finalists represent the chemistry stars of the future. Having seen the reviews and read the submissions I know that identifying this year's overall three winners from these finalists will be extremely tough for the Reaxys PhD Prize Committee".
All finalists are invited to attend and present their work at the Reaxys PhD Prize Symposium which will be held at the 244th ACS National Meeting & Exposition, on Sunday August 19 2012, in Philadelphia, USA. A travel bursary will be provided to support attendance and registration fees for the conference.
The final selection of the winners of the 2012 Reaxys PhD Prize, will be made by the Reaxys PhD Prize Committee who are all members of the Reaxys Advisory Board:
Prof. A. G. M. Barrett, Imperial College London
Prof. B. M. Trost, Stanford University
Prof. H. N. C. Wong, Chinese University of Hong Kong
The three winners will be announced mid-June. Each of the winners will receive a $2000 check, and will be invited to give a paper at the 2012 Reaxys PhD Prize Symposium.
This year's successful finalists are:
Crisita Atienza, (Princeton University), Marie-Gabrielle Braun, (Ecole Polytechnique, Palaiseau), Sarah Bronner, (University of California, Los Angeles), David Bunck, (Cornell University), Yunfei Cai, (Sichuan University), Mesut Cakmak, (Ludwig-Maximilian University of Munich), Andy Chapman, (University of Bristol), Stefan Benson, (MaxPlanck Institut für Kohlenforschung/ Technical University Dortmund), Nicholas Evans, (University of Oxford), Charles Frazier, (University of California, Santa Barbara), Niankai Fu, (Institute of Chemistry, Chinese Academy of Sciences), Fang Gao, (Boston College), Thomas Gøgsig, (Aarhus University), Gregory L Hamilton, (University of California, San Francisco), Durga Prasada Rao Hari, (Universitaet Regensburg), Phillip Inglesby, (University of Liverpool), Tomohiro Iwai, (Kyoto University), Justin Kim, (Massachusetts Institute of Technology), Andrew Kyle, (University of Oxford), Paraskevi Lagaditis, (University of Toronto), Chi Chung Lee, (University of California, Irvine), Alastair Lennox, (University of Bristol), Zhi Li, (The University of Chicago), Felicitas Lips, (University of Marburg), Min Lu, (Nanyang Technological University), Jie Luo, (National University of Singapore), Matthew R. MacDonald, (University of California, Irvine), Debashis Mandal, (Nagoya University), Steffen Müller, (University of Köln), Kei Murakami, (Kyoto University), Kyungsu Na, (Korea Advanced Institute of Science & Technology), Yuki Naganawa, (Kyoto University), Wesley Sattler, (Columbia University), Joerg Schrittwieser, (University of Graz), Tae Ho Shin, (Kyushu University), Craig Stivala, (University of California, Santa Barbara), Kenji Sumida, (University of California, Berkeley), Basker Sundararaju, (Université de Rennes 1 , Rennes, France), Takayuki Tanaka, (Kyoto University), Ryo Tanaka, (The University of Tokyo), Philipp Winter, (Dortmund University of Technology), Miao Yu, (Boston College), Wei Zhang, (The University of Tokyo), Fangrui Zhong, (National University of Singapore), Zhiwei Zuo, (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences).
Reaxys is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys continues to reflect how chemists think and work. For more information please visit www.reaxys.com/info
Reaxys® is a trademark owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
About Reed Elsevier Properties SA
Reed Elsevier Properties SA is a centre of excellence within Reed Elsevier for the management, development and protection of intellectual property. Reed Elsevier Properties SA owns the PharmaPendium and Reaxys databases. Trademarks including Reaxys®, PharmaPendium®, Targetinsights™, The Lancet® and World Travel Market® are owned and protected by Reed Elsevier Properties SA and used under licence.
Vice President, Global Corporate Relations, Elsevier